BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. Vyondys golodirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT) was the...
BioCentury | Apr 23, 2020
Finance

RNA epigenetic cancer company Accent adds $63M in series B round

Accent has raised $63 million in a series B financing to progress at least one RNA modification program for cancer into the clinic. Existing investor EcoR1 Capital led the round. New investors GV, AbbVie Ventures,...
BioCentury | Mar 25, 2020
Product Development

COVID-19 roundup: Emergency use of Moderna vaccine could come earlier than expected; plus ASCO goes virtual, Galapagos pauses filgotinib trials and more

The overarching news was negative for biopharma Tuesday, with a fresh round of companies announcing trial delays. But Moderna offered a rare ray of light, hinting that its vaccine could be available sooner than many...
BioCentury | Mar 12, 2020
Finance

Silverback raises $78.5M series B to send innate immunity activating therapies to clinic

As Silverback prepares to enter the clinic this year with its lead antibody-based cancer therapy, the biotech raised $78.5 million in a series B. U.S. Venture Partners, which led the round, was drawn to the...
BioCentury | Feb 18, 2020
Politics, Policy & Law

Sharpless' homecoming: the NCI chief's lessons from his time at FDA

NCI Director Ned Sharpless has returned from his seven month stint as acting FDA Commissioner aiming to take on the regulatory hurdles that lie ahead for promising technologies, and seeking ways for NCI's grants to...
BioCentury | Sep 9, 2019
Company News

BeiGene pushes back on short seller report

BeiGene refuted claims by short seller J Capital that the company has reported “fake sales” of its cancer portfolio from Celgene. John Oyler, CEO of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), told BioCentury, “It’s easy to see...
BioCentury | Aug 23, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2019

...Therapeutic targets Infectious disease Norovirus infection Norovirus non-structural protein 1 (Norovirus NS1) Vaccinating against norovirus NS1...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Bivalent degraders of HCV NS3/4A protease complex for HCV infection

DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis C virus (HCV) Bivalent small molecules targeting the HCV NS3/4A protease complex and CRBN, which recruits E3 ubiquitin ligase and induces proteasomal degradation, could treat HCV. The molecules were...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

...M1; M2 - Influenza virus matrix protein M2; NP - Influenza virus nucleoprotein; NS1 - Influenza virus non-structural protein 1...
...M1; M2 - Influenza virus matrix protein M2; NP - Influenza virus nucleoprotein; NS1 - Influenza virus non-structural protein 1...
...M1 M2 - Influenza virus matrix protein M2 NP - Influenza virus nucleoprotein NS1 - Influenza virus non-structural protein 1...
BioCentury | Jul 11, 2019
Distillery Therapeutics

Vaccine against norovirus NS1 could prevent norovirus infection

...DISEASE CATEGORY: Infectious INDICATION: Norovirus infection A Washington University team showed that vaccinating against norovirus NS1...
...reservoir of intestinal tuft cells. Mice infected by norovirus produced anti-NS1 antibodies, and immunization against NS1...
...than vaccination with a capsid protein or inactivated virus. TARGET/MARKER/PATHWAY: Norovirus nonstructural protein 1 (Norovirus NS1...
Items per page:
1 - 10 of 2026